World Orphan Drug Congress is Europe's meeting place for the rare disease community. The Conference offers strategic keynote plenaries, themed tracks and dedicated networking sessions, you have the chance to really tailor the event to the needs of your day-to-day role.
Exhibitors have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the orphan drugs industry.
Meet and listen to biotech start-ups and investors in our Pitch & Partner track where the most promising companies showcase their orphan drug technology and pipeline.
It’s not just about the conference sessions, we recognise the importance of networking.
With roundtable discussions, themed networking receptions, networking lunches and our networking app we offer plenty of opportunities to network with your peers and continue conversations in good company.
The World Orphan Drug Congress brings together the pioneers doing the most innovative work within the industry and across the whole value chain, to share their unique insights with you.
The event looks at bringing together leaders in the field as well as patient groups, to meet, discuss and progress the industry further.
This is the perfect platform to generate new leads, create brand awareness and launch new products. No other marketing gets you in a room with so many potential customers looking for suppliers.
Sponsorship packages are tailored to meet your specific marketing goals. And, the exhibition floor does sell out, so don’t delay.
Enjoy discussions on:
Cell & Gene Therapies
Partnering & Investment
Global Market Access
Expanded Access Programs
Real World Evidence
Global Patient Advocacy
Value Based Pricing & Reimbursement
Epidemiology & Forecasting
Orphan Drugs Policy
Gene Therapy Development
Head of Patient Access & Commercial Planning
Professor Michael Linden
Former VP Gene Therapy & Head, GMI
Yann Le Cam
Chief Executive Officer
Dr Ségolène Aymé
Founder of Orphanet, Emeritus Research Director
Dr Bruno Sepodes
Chair of COMP
Assoc. Director Highly Specialised Technologies
National Institute For Health and Care Excellence
Genetic Alliance UK
Dr Carlo Incerti
SVP, Head of Global Medical Affairs, CMO
Genzyme, A Sanofi Company
Dr Mathew Pletcher
Head of Rare Disease Discovery
M Ken Kengatharan
Managing Partner, Atheneos Ventures and CEO
President Research & Development
Dr Pedro Franco
Former Scientific Administrator
Dr Alexander Natz
Former Associate Director
Dr Diego Ardigo
Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at Chiesi Group
Senior Advisor to Director
National Center for Advancing Translational Sciences (NCATS), NIH
Chair of RDI and CEO, CORD
Dr Josep Torrent-Farnell
Head of the medicine division